Press Room

Article / Oct 31, 2012

New Technologies in Particle Design

Drug Development and Delivery, October 2012

Interview: Colin Minchom, VP, Particle Design Business Unit

“An issue for customers with a poorly soluble molecule is that any one solubility enhancement technology is likely to have, I believe, a 20% to 40% probability of solving the problem. This means that in order to assure acceptable bioavailability, at least three technologies need to be investigated. The customer would need to contract with three single platform technology companies or be able to engage a single company, such as Hovione, that can apply multiple platforms, to increase the probability of solving the  problem, and deliver the desired outcome.”

Read article here

Also in the Press Room

Press Release / Mar 07, 2018

Hovione sells the iMAX business

Hovione announces that it has concluded the sale of all of the share capital of iMAX Diagnostic Imaging limited.